These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis. Hacksell U; Burstein ES; McFarland K; Mills RG; Williams H Neurochem Res; 2014 Oct; 39(10):2008-17. PubMed ID: 24682754 [TBL] [Abstract][Full Text] [Related]
11. Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease. McFarland K; Price DL; Bonhaus DW Behav Pharmacol; 2011 Oct; 22(7):681-92. PubMed ID: 21921840 [TBL] [Abstract][Full Text] [Related]
12. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563 [TBL] [Abstract][Full Text] [Related]
13. Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin. Lyons KE; Pahwa R; Hermanowicz N; Davis T; Pagan F; Isaacson S Expert Rev Clin Pharmacol; 2019 Jul; 12(7):681-691. PubMed ID: 31159608 [No Abstract] [Full Text] [Related]
14. Pimavanserin for the treatment of Parkinson's disease psychosis. Friedman JH Expert Opin Pharmacother; 2013 Oct; 14(14):1969-75. PubMed ID: 24016069 [TBL] [Abstract][Full Text] [Related]
17. Pimavanserin for the treatment of Parkinson's disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed. Citrome L; Norton JC; Chi-Burris K; Demos G CNS Spectr; 2018 Jun; 23(3):228-238. PubMed ID: 29098976 [TBL] [Abstract][Full Text] [Related]